710 related articles for article (PubMed ID: 33766063)
21. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
22. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
[TBL] [Abstract][Full Text] [Related]
24. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
25. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
27. Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
Ruperto N; Martini A
Georgian Med News; 2008 Mar; (156):68-74. PubMed ID: 18403813
[TBL] [Abstract][Full Text] [Related]
28. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
29. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
32. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
33. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
Ruperto N; Vesely R; Saint-Raymond A; Martini A;
Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
[TBL] [Abstract][Full Text] [Related]
34. Expanded table: some biologic agents and JAK inhibitors for RA.
Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
[No Abstract] [Full Text] [Related]
35. Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis.
Med Lett Drugs Ther; 2021 Nov; 63(1637):e187-e189. PubMed ID: 35085212
[No Abstract] [Full Text] [Related]
36. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
Rathore U; Thakare DR; Patro P; Agarwal V; Sharma A; Misra DP
Clin Rheumatol; 2022 Jan; 41(1):33-44. PubMed ID: 34729652
[TBL] [Abstract][Full Text] [Related]
38. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
39. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
